Showing 1-11 of 11 results for "AB1258"
Xiao-Fei Yin et al.
Oncology reports, 30(1), 364-370 (2013-04-23)
Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor associated with tumor initiation and progression. AhR expression is significantly increased in gastric cancer tissues and gastric cancer cell lines; however, the relationship between AhR and gastric cancer is still unclear....
J Hakkola et al.
Biochemical pharmacology, 51(4), 403-411 (1996-02-23)
The expression of individual xenobiotic-metabolizing cytochrome P450 (CYP) genes in human placenta was studied at the mRNA level by reverse transcriptase-polymerase chain reaction (RT-PCR). mRNAs of CYP1A1, CYP2E1, CYP2F1, CYP3A3/4, CYP3A5, and CYP4B1 were detected by RT-PCR, and CYP1A2, CYP2A6/7...
Y Kapelyukh et al.
Drug metabolism and disposition: the biological fate of chemicals, 47(8), 907-918 (2019-05-31)
Cytochrome P450s CYP1A1 and CYP1A2 can metabolize a broad range of foreign compounds and drugs. However, these enzymes have significantly overlapping substrate specificities. To establish their relative contribution to drug metabolism in vivo, we used a combination of mice humanized...
A Kenneth MacLeod et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(9), 2138-2147 (2018-02-14)
Purpose: Osimertinib is a third-generation inhibitor of the epidermal growth factor receptor used in treatment of non-small cell lung cancer. A full understanding of its disposition and capacity for interaction with other medications will facilitate its effective use as a...
Elevated expression of CYP1A1 and gamma-SYNUCLEIN in human ectopic (ovarian) endometriosis compared with eutopic endometrium.
Singh, MN; Stringfellow, HF; Taylor, SE; Ashton, KM; Ahmad, M; Abdo, KR; El-Agnaf et al.
Molecular Human Reproduction null
Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9.
Peng, TL; Chen, J; Mao, W; Song, X; Chen, MH
BMC Cell Biology null
Mingli Su et al.
Oncology letters, 14(6), 8100-8105 (2018-01-19)
3'3-Diindolylmethane (DIM) has been proved to exhibit anticancer properties in many solid tumors. In our previous study, we demonstrated that DIM inhibited SGC7901 cell proliferation by inducing apoptosis and delaying cell cycle progression. Herein, we further explored the anti-tumor effect...
Tie-Li Peng et al.
World journal of gastroenterology, 15(14), 1719-1729 (2009-04-11)
To determine the functional significance of aryl hydrocarbon receptor (AhR) in gastric carcinogenesis, and to explore the possible role of AhR in gastric cancer (GC) treatment. RT-PCR, real-time PCR, and Western blotting were performed to detect AhR expression in 39...
Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-I?1.
Koch, et al.
Oncogene, 34, 6092-6104 (2018)
De Lin et al.
The Journal of pharmacology and experimental therapeutics, 363(1), 12-19 (2017-09-09)
Ponatinib, a pan-BCR-ABL tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML), causes severe side effects including vascular occlusions, pancreatitis, and liver toxicity, although the underlying mechanisms remain unclear. Modifications of critical proteins through reactive metabolites are thought...
Xiao-Fei Yin et al.
Journal of experimental & clinical cancer research : CR, 31, 46-46 (2012-05-18)
Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor associated with gastric carcinogenesis. 3,3'-Diindolylmethane (DIM) is a relatively non-toxic selective AhR modulator. This study was to detect the effects of DIM on gastric cancer cell growth. Gastric cancer cell SGC7901...

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.